Diabetic Macular Edema - Pipeline Review, H1 2020

January 2020 | 298 pages | ID: D8CCFF17EC6EN
Global Markets Direct

Abstracts

Diabetic Macular Edema - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2020, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 19, 15, 5, 50, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Diabetic Macular Edema - Overview
Diabetic Macular Edema - Therapeutics Development
Diabetic Macular Edema - Therapeutics Assessment
Diabetic Macular Edema - Companies Involved in Therapeutics Development
Diabetic Macular Edema - Drug Profiles
Diabetic Macular Edema - Dormant Projects
Diabetic Macular Edema - Discontinued Products
Diabetic Macular Edema - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Diabetic Macular Edema - Pipeline by 3SBio Inc, H1 2020
Diabetic Macular Edema - Pipeline by Abpro Corp, H1 2020
Diabetic Macular Edema - Pipeline by Aciont Inc, H1 2020
Diabetic Macular Edema - Pipeline by Acucela Inc, H1 2020
Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Aerpio Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Allegro Ophthalmics LLC, H1 2020
Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2020
Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Apexian Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Ascentage Pharma Group International, H1 2020
Diabetic Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by BetaStem Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Bio-Thera Solutions Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Diabetic Macular Edema - Pipeline by Cell Care Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Celon Pharma SA, H1 2020
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Chiome Bioscience Inc, H1 2020
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020
Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020
Diabetic Macular Edema - Pipeline by Elasmogen Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Eleusis Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Everglades Biopharma LLC, H1 2020
Diabetic Macular Edema - Pipeline by Exonate Ltd, H1 2020
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Eyevensys SAS, H1 2020
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Formycon AG, H1 2020
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2020
Diabetic Macular Edema - Pipeline by Graybug Vision Inc, H1 2020
Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, H1 2020
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by Kodiak Sciences Inc, H1 2020
Diabetic Macular Edema - Pipeline by Kowa Co Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Lupin Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2020
Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Diabetic Macular Edema - Pipeline by NeuBase Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by NeuMedics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Novartis AG, H1 2020
Diabetic Macular Edema - Pipeline by Novelty Nobility Inc, H1 2020
Diabetic Macular Edema - Pipeline by OccuRx Pty Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Ocugen Inc, H1 2020
Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H1 2020
Diabetic Macular Edema - Pipeline by Oculis SA, H1 2020
Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Opthea Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Outlook Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by Oxurion NV, H1 2020
Diabetic Macular Edema - Pipeline by Pfizer Inc, H1 2020
Diabetic Macular Edema - Pipeline by Phanes Therapeutics Inc, H1 2020
Diabetic Macular Edema - Pipeline by PharmAbcine Inc, H1 2020
Diabetic Macular Edema - Pipeline by Pleryon Therapeutics Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Profarma, H1 2020
Diabetic Macular Edema - Pipeline by Protheragen Inc, H1 2020
Diabetic Macular Edema - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020
Diabetic Macular Edema - Pipeline by RemeGen Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Rezolute Inc, H1 2020
Diabetic Macular Edema - Pipeline by RiniSight Inc, H1 2020
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H1 2020
Diabetic Macular Edema - Pipeline by Semathera Inc, H1 2020
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H1 2020
Diabetic Macular Edema - Pipeline by Suzhou Stainwei Biotech Inc, H1 2020
Diabetic Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020
Diabetic Macular Edema - Pipeline by Theravance Biopharma Inc, H1 2020
Diabetic Macular Edema - Pipeline by Verseon Corp, H1 2020
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020
Diabetic Macular Edema - Pipeline by YD Life Science Co, H1 2020
Diabetic Macular Edema - Dormant Projects, H1 2020
Diabetic Macular Edema - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
Abpro Corp
Aciont Inc
Acucela Inc
Aerie Pharmaceuticals Inc
Aerpio Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allergan Plc
Allgenesis Biotherapeutics Inc
Ampio Pharmaceuticals Inc
Apexian Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
AsclepiX Therapeutics Inc
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
Boehringer Ingelheim International GmbH
Cell Care Therapeutics Inc
Cell Medica Ltd
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chiome Bioscience Inc
Clearside BioMedical Inc
Coherus BioSciences Inc
Elasmogen Ltd
Eleusis Ltd
Everglades Biopharma LLC
Exonate Ltd
EyeGate Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Formycon AG
Gene Signal International SA
Graybug Vision Inc
Isarna Therapeutics GmbH
Kalvista Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
Momenta Pharmaceuticals Inc
NeuBase Therapeutics Inc
NeuMedics Inc
Novartis AG
Novelty Nobility Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
OcuNexus Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxurion NV
Pfizer Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Pleryon Therapeutics Ltd
Profarma
Protheragen Inc
Qilu Pharmaceutical Co Ltd
RemeGen Ltd
Rezolute Inc
RiniSight Inc
SciFluor Life Sciences LLC
Semathera Inc
Senju Pharmaceutical Co Ltd
Suzhou Stainwei Biotech Inc
Targeted Therapy Technologies LLC
Theravance Biopharma Inc
Verseon Corp
Xbrane Biopharma AB
YD Life Science Co